Literature DB >> 16865075

Comparison of remifentanil or fentanyl administration during isoflurane anesthesia for coronary artery bypass surgery.

Małgorzata Knapik1, Piotr Knapik, Paweł Nadziakiewicz, Hanna Misiołek, Wojciech Saucha, Małgorzata Walaszczyk, Anna Dyaczyńska-Herman.   

Abstract

BACKGROUND: The combination of inhalational agents with moderate doses of fentanyl is popular in cardiac anesthesia. Remifentanil is a new opioid metabolized by non-specific esterases. The aim of our study was to assess whether remifentanil may be superior to fentanyl during isoflurane anesthesia for coronary artery surgery. MATERIAL/
METHODS: Forty patients aged 40-70 years with stable coronary artery disease were randomly allocated to two groups: remifentanil was used in 20 patients (group I) and fentanyl was used in 20 patients (group II). Induction of anesthesia was performed with remifentanil infusion (0.5 microg/kg/min) or a bolus dose of fentanyl (5 microg/kg) followed by a bolus of etomidate and pancuronium. Maintenance of anesthesia was provided by isoflurane and infusion of the study opioid, with the rate adjusted according to systolic blood pressure values. Hemodynamic parameters were registered before and after the induction of anesthesia, skin incision, sternotomy, aortic cannulation, termination of cardiopulmonary bypass, chest closure, and skin closure.
RESULTS: Heart rate and mean arterial pressure values were significantly lower in the remifentanil group, while systemic vascular resistance was higher in the fentanyl group in the measurements taken before the initiation of cardiopulmonary bypass. No differences were found between groups in the values of mean pulmonary pressure, pulmonary artery wedge pressure and transpulmonary pressure gradient, central venous pressure, and cardiac index.
CONCLUSIONS: Remifentanil is safe during inhalation anesthesia for coronary artery surgery and it appears to be more effective than fentanyl in blunting hemodynamic response before the initiation of cardiopulmonary bypass surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865075

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

Review 1.  Fast-track cardiac care for adult cardiac surgical patients.

Authors:  Wai-Tat Wong; Veronica Kw Lai; Yee Eot Chee; Anna Lee
Journal:  Cochrane Database Syst Rev       Date:  2016-09-12

2.  Priming with rocuronium or vecuronium prevents remifentanil-mediated muscle rigidity and difficult ventilation.

Authors:  Junya Nakada; Masao Nishira; Renko Hosoda; Kazumi Funaki; Shyunsaku Takahashi; Tatsuya Matsura; Yoshimi Inagaki
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

3.  Remifentanil prevents increases of blood glucose and lactate levels during cardiopulmonary bypass in pediatric cardiac surgery.

Authors:  Tomohiro Chaki; Yuko Nawa; Keishi Tamashiro; Eri Mizuno; Naoyuki Hirata; Michiaki Yamakage
Journal:  Ann Card Anaesth       Date:  2017 Jan-Mar

Review 4.  Could remifentanil reduce duration of mechanical ventilation in comparison with other opioids for mechanically ventilated patients? A systematic review and meta-analysis.

Authors:  Yibing Zhu; Yinhua Wang; Bin Du; Xiuming Xi
Journal:  Crit Care       Date:  2017-08-03       Impact factor: 9.097

5.  Effects of high thoracic epidural anesthesia on mixed venous oxygen saturation in coronary artery bypass grafting surgery.

Authors:  Ercan Gurses; Derviş Berk; Hülya Sungurtekin; Aslı Mete; Simay Serin
Journal:  Med Sci Monit       Date:  2013-03-27

6.  A case series of continuous paravertebral block in minimally invasive cardiac surgery.

Authors:  Shintaro Tahara; Akito Inoue; Hajime Sakamoto; Yasuaki Tatara; Kayoko Masuda; Yoichiro Hattori; Yusaku Nozumi; Mitsumasa Miyagi; Surakshya Sigdel
Journal:  JA Clin Rep       Date:  2017-08-29

Review 7.  Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.

Authors:  Amie L Severino; Arash Shadfar; Joshua K Hakimian; Oliver Crane; Ganeev Singh; Keith Heinzerling; Wendy M Walwyn
Journal:  Front Psychiatry       Date:  2018-04-23       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.